At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 323 enrolled

Drug / intervention

Natamycin +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00996736

NCT00996736Phase 3Completed

Compare CT.gov

Mycotic Ulcer Treatment Trial

University of California, San Francisco·interventional·Posted Oct 16, 2009·Updated Aug 1, 2018

In Brief

A Phase 3 clinical trial evaluating Natamycin and Voriconazole for Corneal Ulcer and Eye Infections, Fungal. Completed, enrolled 323 participants across 3 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine if natamycin or voriconazole results in better visual outcomes in fungal corneal ulcers, especially visual acuity.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsCorneal Ulcer, Eye Infections, Fungal

CountriesIndia, United States

CollaboratorsAravind Eye Hospitals, India, Dartmouth-Hitchcock Medical Center, National Eye Institute (NEI)

Timeline

Phase 3CompletedFinished

20102011201220132014201520162017201820192020202120222023202420252026

First PostedOct 2009

Enrollment StartApr 2010

Primary CompletionJul 2012

TodayJul 2026

First PostedOct 16, 2009

Enrollment StartApr 1, 2010

Primary CompletionJul 1, 2012

TodayJul 2, 2026

Enrollment to primary: 2.3 yearsPosted 16.7 years ago

Interventions

Natamycindrug

5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.

Voriconazoledrug

1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.